Australia markets closed

Oculis Holding AG (CR5.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
10.80-0.10 (-0.92%)
At close: 09:59PM CEST
Full screen
Previous close10.90
Open10.90
Bid10.80 x N/A
Ask11.20 x N/A
Day's range10.80 - 10.90
52-week range8.45 - 13.00
Volume0
Avg. volume5
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Oculis updates share capital for its existing at-the-market offering program

    ZUG, May 17, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01, issued out of existing capital band (Kapitalband), for an aggregate of 1,000,000 ordinary shares of the Company (the "New Shares"), recorded as treasury shares. The number of registered shares issued by the Company as per its Articles of Association is 46,443,7

  • GlobeNewswire

    Oculis Reports Q1 2024 Financial Results and Provides Company Updates

    Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye Disease (DED); RELIEF topline results anticipated in Q2 2024Completed $59 million registered direct equity offering and concurrent listing on Nasdaq Iceland Main Market in April 2024, extending cash runway into the second half of 2026Strengthened executive leadership team and U.S. p

  • GlobeNewswire

    Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis

    Topline results anticipated in Q4 2024 for Phase 2 trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis (AON)Oculis also aims to complete an IND submission for OCS-05 in the U.S. in 2024OCS-05 has been granted orphan drug designation in the United States and Europe for AON, an indication for which there are no approved therapies ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a glob